Effects of Specific Multi-Nutrient Enriched Diets on Cerebral Metabolism, Cognition and Neuropathology in AβPPswe-PS1dE9 Mice

Diane Jansen¹, Valerio Zerbi¹, Ilse A. C. Arnoldussen¹, Maximilian Wiesmann¹, Anne Rijpma¹, Xiaotian T. Fang¹, Pieter J. Dederen¹, Martina P. C. Mutsaers¹, Laus M. Broersen², Dieter Lütjohann³, Malgorzata Miller⁴, Leo A. B. Joosten⁴, Arend Heerschap⁵, Amanda J. Kiliaan¹*¹

¹Department of Anatomy, Radboud University Nijmegen Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands, 2Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands, 3Institute for Clinical Chemistry and Clinical Pharmacology, University Clinics Bonn, Bonn, Germany, 4Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen Institute for Infection, Inflammation and Immunity, Nijmegen, The Netherlands, 5Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Abstract

Recent studies have focused on the use of multi-nutrient dietary interventions in search of alternatives for the treatment and prevention of Alzheimer’s disease (AD). In this study we investigated to which extent long-term consumption of two specific multi-nutrient diets can modulate AD-related etiopathogenic mechanisms and behavior in 11-12-month-old AβPPswe-PS1dE9 mice. Starting from 2 months of age, male AβPP-PS1 mice and wild-type littermates were fed either a control diet, the DHA+EPA+UMP (DEU) diet enriched with uridine monophosphate (UMP) and the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), or the Fortasyn® Connect (FC) diet enriched with the DEU diet plus phospholipids, choline, folic acid, vitamins and antioxidants. We performed behavioral testing, proton magnetic resonance spectroscopy, immunohistochemistry, biochemical analyses and quantitative real-time PCR to gain a better understanding of the potential mechanisms by which these multi-nutrient diets exert protective properties against AD. Our results show that both diets were equally effective in changing brain fatty acid and cholesterol profiles. However, the diets differentially affected AD-related pathologies and behavioral measures, suggesting that the effectiveness of specific nutrients may depend on the dietary context in which they are provided. The FC diet was more effective than the DEU diet in counteracting neurodegenerative aspects of AD and enhancing processes involved in neuronal maintenance and repair. Both diets elevated interleukin-1β mRNA levels in AβPP-PS1 and wild-type mice. The FC diet additionally restored neurogenesis in AβPP-PS1 mice, decreased hippocampal levels of unbound choline-containing compounds in wild-type and AβPP-PS1 animals, suggesting diminished membrane turnover, and decreased anxiety-related behavior in the open field behavior. In conclusion, the current data indicate that specific multi-nutrient diets can influence AD-related etiopathogenic processes. Intervention with the FC diet might be of interest for several other neurodegenerative and neurological disorders.

Introduction

Alzheimer’s disease (AD) is a complex neurodegenerative disorder that affects over 36 million people worldwide. The exact cause of AD is still largely unknown despite over 100 years of extensive research, and still no curative treatments are available. Aging is recognized as the main risk factor for the late-onset sporadic form of AD (SAD), while early-onset familial AD (FAD) has been linked to autosomal dominant mutations in the gene for the amyloid-β precursor protein (AβPP) and the genes for the presenilin 1 (PS1) and presenilin 2 (PS2) proteins [1,2]. Both SAD and FAD share specific neuropathologic features, including neurofibrillary tangles, amyloid-β (Aβ) plaques, neuronal loss, white matter lesions and synaptic changes in vulnerable brain regions such as the hippocampus and neocortex [3,4]. For decades, the production and accumulation of the Aβ peptide has been proposed to be the primary trigger of the pathological cascade leading to neurodegeneration and the development of AD. Besides Aβ, several other (risk) factors have been proposed to play an important role in the development of AD.

Many large epidemiological studies have demonstrated that vascular disorders, such as hypercholesterolemia and atherosclerosis, are important risk factors for AD [5–7]. Furthermore, cardiovascular disease risk factors, such as a sedentary lifestyle, high saturated fatty acid (SFA) intake, diabetes, smoking and obesity, are associated with a higher risk of developing AD and...
other dementias [8–11]. Many of these cardiovascular risk factors are modifiable [12]. Modifying cardiovascular risk factors, for example by changing lifestyle, might ultimately also affect the risk of developing AD.

Due to the limited and short-lasting efficacy of the current drugs available [12], recent work has focused on the use of dietary interventions for the treatment and prevention of AD. Omega-3 long-chain poly-unsaturated fatty acids (n3-PUFAs), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), have shown protective properties with regard to risk of age-related cognitive decline and AD [13–16]. The mechanisms by which these dietary nutrients exert protective properties against AD are still under investigation, but several lines of evidence have shown beneficial effects of n3-PUFAs on the cardiovascular system [17,18] and on neuronal membrane properties [19,20]. These beneficial effects on the cardiovascular system have been explained by the capacity to decrease blood pressure [21], lower plasma triacylglycerols [22,23], prevent arrhythmias [24], improve vascular reactivity [25,26], decrease atherosclerosis [27], and suppress inflammatory processes [28]. Furthermore, high levels of n3-PUFAs replace omega-6 fatty acids (n6 FAs) and cholesterol from cell membranes, leading to increased membrane fluidity, increased number of receptors, enhanced receptor binding and affinity, better ion channel functionality, and modulation of gene expression of many enzyme proteins involved in signal transduction processes [29–31]. As a result, this will lead to improved neurotransmission and signaling [32], which is important for optimal cognitive functioning [33]. Other dietary components, like B vitamins and antioxidants, have also been shown to protect the brain from oxidative and inflammatory damage [34–36], and synaptic and neuronal loss [37,38]. However, when tested in a clinical setting supplementation with single nutrients is marginally effective in improving disease status [39–42]. It has been suggested that approaches with multiple nutritional components might be more promising, since not individual nutrients but dietary patterns that approaches with multiple nutritional components might be more promising, since not individual nutrients but dietary patterns were identified as a factor influencing the risk of developing AD [43].

Combined administration of different nutrients has shown increased effectiveness in altering specific parameters involved in AD. Supplementation with DHA or uridine monophosphate (UMP) improved water maze performance of environmentally impoverished rats. However, the combined administration of DHA and UMP was more effective in improving learning abilities [44]. Furthermore, performance on the four-arm radial maze, T-maze and Y-maze tests by normal adult gerbils was improved by supplementation of DHA and choline, and was even further enhanced by coadministering UMP [45]. In addition to enhancing cognitive performance, combinations of nutrients were shown to be more effective than single nutrients in counteracting neurodegenerative aspects of AD [38,46,47] and enhancing processes involved in neuronal regeneration and function [48–50]. Moreover, clinical trials with combinations of nutrients have shown beneficial effects on memory performance in patients with mild AD [51–53].

In the current study, we wanted to investigate the extent to which long-term consumption of two specific multi-nutrients diets can modulate behavior, cognition, hippocampal metabolite levels, neurogenesis and inflammation in 11-12-month-old AβPP-PS1 mice. Starting from 2 months of age, animals were fed either a control diet, a multi-nutrient diet enriched with DHA, EPA and UMP (DEU), or a multi-nutrient diet enriched with DHA, EPA, UMP, phospholipids, choline, folic acid, vitamins B6, B12, C, E and selenium (Fortasyn® Connect). We performed behavioral testing, proton magnetic resonance spectroscopy (1H MRS), immunohistochemistry, biochemical analyses and quantitative real-time PCR to gain a better understanding of the potential mechanisms by which these multi-nutrient diets may exert protective properties against AD.

**Animals, Materials and Methods**

**Ethics statement, animals and housing conditions**

The experiments were performed according to Dutch federal regulations for animal protection and were approved by the Veterinary Authority of the Radboud University Nijmegen Medical Centre (Permit Number: RU-DEC 2008-126b). All efforts were made to minimize suffering of the animals.

The AβPPswec-PS1dE9 founders were originally obtained from Johns Hopkins University, Baltimore, MD, USA (D. Borchelt and J. Jankowsky, Dept. of Pathology) and a colony was established at the Radboud University Nijmegen Medical Centre, The Netherlands. In short, mice were created by co-injection of chimeric mouse/human AβPPswec (mouse AβPP695 harboring a human Aβ domain and mutations K355N and M596L, linked to Swedish familial AD pedigrees) and human PS1dE9 (deletion of exon 9) vectors controlled by independent mouse prion protein promoter elements. The two transfected genes co-integrate and co-segregate as a single locus [34,55]. This line (line 83) was originally maintained on a hybrid background by backcrossing to C3HfC57BL6/J F1 mice (so-called pseudo F2 stage). For the present work, the breeder mice were backcrossed to C57BL6/J for 13 generations to obtain mice for the current study. Throughout the experiment, animals were housed in groups of 2–6 mice per cage in a controlled environment, homogenously illuminated by natural fluorescent room light at 60 lux, with room temperature at 21°C, and an artificial 12:12 h light:dark cycle (lights on at 7 a.m.). Food and water were available ad libitum.

Male transgenic AβPP-PS1 mice and their wild-type littermates were fed either 1) a standard Control diet (CO diet), 2) a multi-nutrient diet enriched with DHA, EPA and UMP (DEU diet), or 3) a multi-nutrient diet, called Fortasyn® Connect (FC diet), containing precursors and cofactors in membrane synthesis and maintenance via the Kennedy cycle [56], such as DHA, EPA, UMP, phospholipids, choline, vitamins B6, B9, B12, C and E, folic acid and selenium. The diets differed in composition with regard to the fat blends used, as well as a number of supplemented nutrients as indicated in Table 1. Diets were isocaloric and were manufactured by Research Diet Services (Wijk bij Duurstede, The Netherlands). In order to minimize oxidation of the n3-PUFAs, the experimental diets were stored at −20°C in 2-day supply aliquots. Feeding the diets started when the mice reached the age of 2 months and was maintained for the remainder of the experiment. Animals underwent behavioral testing at 11 months of age and subsequently MRI measurements at 12 months of age (Figure 1). In total, 85 mice were used in the current study. Table 2 describes the number of mice used in each experimental group. The body weight of the mice was determined one week before the start of the behavioral tests at 11 months of age, and again on the day of the MRI measurements at 12 months of age.

**Behavioral analyses**

Behavioral testing was performed in the following order (Figure 1): First open field, followed by the Morris water maze (MWM), and finally the reversal MWM (rMWM). All testing sessions were performed during the light phase (between 9 a.m. and 5 p.m.) and were recorded for computer-assisted analysis using Ethovision XT 7.0 software (Noldus Information Technology B.V., Wageningen, The Netherlands). All behavioral testing was...
performed in the same room, homogenously illuminated by normal fluorescent room light at 60 lux.

**Open field.** To analyze explorative and anxiety-related behavior, mice were placed individually in the center of a square open field (50×50×40 cm) with white Plexiglas walls. Animals were observed for 30 minutes, and the durations (seconds) of walking, wall leaning, rearing, sitting and grooming were scored and analyzed. These open field parameters were defined as described previously [57,58]. In addition, total walking distance, mean velocity, and the time spent in the corners and in the center of the open field were obtained from the recorded sessions. The mean velocity, and the time spent in the corners and in the center of the open field were defined as the sum of all four 10 cm squared corners.

**Morris water maze (MWM).** To investigate spatial learning abilities, mice were tested in the Morris water maze (MWM). In short, mice were placed in a pool (104 cm diameter) at different starting positions and were trained to find a submerged platform by using distant visual cues in the room. The water was made opaque by the addition of milk powder, and was kept at a constant temperature of 21-22°C. The maze was surrounded by white curtains at a distance of 0.5 meter, which were marked by four spatial cues varying in shape, size and color. The 8 cm diameter round platform was submerged 1 cm below the water surface and was placed in the middle of the northeast (NE) quadrant at a distance of approximately 26 cm from the wall. The researcher was always present at the same location in the room during all trials (close to the southwest quadrant).

**Behavioral testing** was performed on a 11.7T BioSpec Avance III small animal MR system (Bruker BioSpin, Ettlingen, Germany) equipped with an actively shielded gradient set of 600 mT/m. A circular polarized volume resonator was used for signal transmission and an actively decoupled mouse brain quadrature surface coil was used for signal detection (Bruker BioSpin). During the experiments, mice were anesthetized with 3.5% isoflurane (Nicholas Primal [I] limited, London, United Kingdom) for induction and 2% isoflurane for maintenance in a mixture of N2O and oxygen (1:2) through a nose cone. The anesthetic concentration was adjusted during the experiment in order to maintain the breathing frequency at 70–100 per minute. Respiration of the animal was monitored using a pneumatic cushion respiratory monitoring system (Small Animal Instruments Inc., NY, USA). Body temperature was measured using a rectal thermometer and maintained at 37°C using a heated air flow device. Mice were placed in a stereotactic holder in order to immobilize the head and prevent unwanted movement during the MRI measurements were performed on a 11.7T BioSpec Avance III small animal MR system (Bruker BioSpin, Ettlingen, Germany) equipped with an actively shielded gradient set of 600 mT/m. A circular polarized volume resonator was used for signal transmission and an actively decoupled mouse brain quadrature surface coil was used for signal detection (Bruker BioSpin). During the experiments, mice were anesthetized with 3.5% isoflurane (Nicholas Primal [I] limited, London, United Kingdom) for induction and 2% isoflurane for maintenance in a mixture of N2O and oxygen (1:2) through a nose cone. The anesthetic concentration was adjusted during the experiment in order to maintain the breathing frequency at 70–100 per minute. Respiration of the animal was monitored using a pneumatic cushion respiratory monitoring system (Small Animal Instruments Inc., NY, USA). Body temperature was measured using a rectal thermometer and maintained at 37°C using a heated air flow device. Mice were placed in a stereotactic holder in order to immobilize the head and prevent unwanted movement during the

Figure 1. Time line of experimental design. At 2 months of age, APP-PS1 mice and their wild-type littermates were put on either a control diet (CO), a DHA, EPA and UMP diet (DEU) or a Fortasyn® Connect diet (FC) for the remainder of the experiment. Behavioral testing was performed at 11 months of age. Animals were weighed one week before starting the behavioral testing battery. In the first week of behavioral testing, animals were exposed to the open field once for 30 minutes. In the second week, animals were trained in the Morris water maze (MWM) for 4 days. In the third week, animals were trained in the reverse Morris water maze (rMWM) for 2 days. MR imaging was performed at 12 months of age. Mice were weighed before MR imaging and sacrificed immediately after MR imaging.

doi:10.1371/journal.pone.0075393.g001
scanning. Gradient echo (GE) images in the axial, sagittal and coronal orientation were acquired to visualize the anatomy of the mouse brain structures. Imaging parameters were: echo time (TE) = 5 ms, repetition time (TR) = 630 ms, flip angle = 12 deg, field of view (FOV) = 40 × 40 mm, matrix size = 512 × 512, slice thickness = 0.345 mm.

Magnetic resonance spectroscopy (MRS). Metabolite concentrations in the hippocampus were determined using 1H

**Table 1.** Compositions of the experimental diets used, based on AIN-93M [172] with minor revisions.

| Source                      | Control (CO) | DHA, EPA, UMP (DEU) | Fortasyn® Connect (FC) |
|-----------------------------|--------------|----------------------|------------------------|
|                             | g/100 g of diet | g/100 g of diet       | g/100 g of diet         |
| Corn Starch                 | 35.57        | 34.57                | 33.12                  |
| Casein (>85% protein)       | 14.00        | 14.00                | 14.00                  |
| Corn dextrin                | 15.50        | 15.50                | 15.50                  |
| Sucrose                     | 10.00        | 10.00                | 10.00                  |
| Dextrose                    | 10.00        | 10.00                | 10.00                  |
| Fibers                      | 5.00         | 5.00                 | 5.00                   |
| Mineral mix (AIN-93M-MX)    | 3.50         | 3.50                 | 3.50                   |
| Vitamin mix (AIN-93-VX)     | 1.00         | 1.00                 | 1.00                   |
| Soy oil                     | 1.900        | –                    | –                      |
| Coconut oil                 | 0.900        | 0.100                | 0.100                  |
| Corn oil                    | 2.200        | 1.870                | 1.870                  |
| Fish oil                    | –            | 3.030                | 3.030                  |
| L-cysteine                  | 0.180        | 0.180                | 0.180                  |
| Choline bitartrate (41.1% choline) | 0.250        | 0.250                | 0.250                  |
| Tert-butylhydroquinone      | 0.0008       | 0.0008               | 0.0008                 |
| Pyridoxine-HCl              | –            | –                    | 0.00328                |
| Folic acid (90%)            | –            | –                    | 0.00067                |
| Cyanocobalamin (0.1% in mannitol) | –            | –                    | 0.00350                |
| Ascorbic acid (100% pure)   | –            | –                    | 0.160                  |
| dl-α-tocopheryl acetate (500 IU/g) | –            | –                    | 0.4650                 |
| UMP disodium (24% H2O)      | –            | 1.0                  | 1.0                    |
| Choline chloride (74.576%)  | –            | –                    | 0.402                  |
| Soy lecithin                | –            | –                    | 0.402                  |
| Sodium selenite (46% min)   | –            | –                    | 0.00023                |
| Energy (kcal/100 g chow)    | **376.9**    | **372.9**            | **367.1**              |

All diets were isoenergetic, contained 5% fat and standard vitamin and mineral premix, providing recommended daily amounts of these nutrients. DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; UMP = uridine monophosphate.

doi:10.1371/journal.pone.0075393.t001

**Table 2.** Overview of the number of mice used in each experimental group.

| Genotype | Diet  | Total | OF | (r)MWM | MRS | IHC | BCH |
|----------|-------|-------|----|--------|-----|-----|-----|
| Wild-type| CO    | 20    | 20 | 13–15  | 15  | 9   |
|          | DEU   | 17    | 17 | 13–15  | 8   | 8   |
|          | FC    | 16    | 16 | 14–15  | 16  | 7   |
| AbPP-PS1 | CO    | 14    | 14 | 13     | 10  | 5–7 | 5   |
|          | DEU   | 8     | 8  | 7      | 4–5 | 3   |
|          | FC    | 10    | 10 | 7      | 4–6 | 4   |

CO = Control diet; DEU = DHA, EPA, UMP diet; FC = Fortasyn® Connect diet; OF = open field; (r)MWM = (reverse) Morris water maze; MRS = magnetic resonance spectroscopy; IHC = immunohistochemistry; BCH = biochemistry.

doi:10.1371/journal.pone.0075393.t002
MRS with single voxel technique. The spectroscopic volume of interest (VOI) of 1.0 x 1.0 x 2.0 mm was positioned unilaterally in the right hippocampus based on the acquired anatomical images. Water-suppressed 1H-MRS spectra were acquired with a point-resolved spectroscopy sequence (PRESS) with a short echo time with imaging parameters: TE = 10.905 ms, TR = 2500 ms, T1 = 6.31 ms, T2 = 4.59 ms, and 800 signal averages. Total acquisition time for 1H MRS was 27 min per animal.

Quantification of the metabolite concentration was performed using a linear combination (LC) model software package (LCModelTM, S. Provencher, Oakville, Canada). The quantification algorithm of LCModelTM applies linear combinations of model spectra to calculate the best fit of the experimental spectrum. The model spectra (dataset of prior knowledge) were calibrated to match the magnetic field strength, sequence type and sequence parameters used for data acquisition.

The criteria to select reliable metabolite tissue concentrations were based on the Cramér-Rao lower bounds (CRLB), which are estimates of the S.D. of the fit for each metabolite [61] as determined by LCModelTM. Only CRLB ≤20% were included in the analysis. Concentrations with CRLB >20% were classified as not detected. Six metabolites fulfilled the criteria: choline + glycerophosphocholine + phosphocholine (tCho; choline-containing compounds), creatine + phosphocreatine (tCr), glutamine + glutamate (Glx), myo-Inositol + glycerol (mI+Gly), N-acetylaspartate + N-acetylaspartylglutamate (tNAA) and taurine (Tau). Although the exact functions of these metabolites are not fully known, tNAA is considered to be a marker of neuronal viability, tCr is involved in energy metabolism, mI is a putative marker for microglia and astrogliosis, and tCho is required for the synthesis of the neurotransmitter acetylcholine, and of phosphatidylcholine, a major constituent of membranes, and is therefore associated with membrane turnover [62].

Tissue sampling

Directly following the MR measurements at 12 months of age, half of the number of mice was sacrificed by cervical dislocation to collect blood samples and brain tissue for biochemical analyses, and the other half was sacrificed by transcardial perfusion fixation with 4% paraformaldehyde (4% paraformaldehyde in 0.1 M phosphate buffered saline (PBS; pH = 7.3) to collect brains for immunohistochemical stainings. Blood samples were collected via eye extraction, and subsequently processed to obtain blood serum. Blood serum was stored at -80°C, before further biochemical processing. Non-perfused brains were snap frozen in liquid nitrogen and then stored at -80°C, before further biochemical processing. Perfused brains were collected and postfixed for 15 h at 4°C in 4% paraformaldehyde fixative and subsequently stored in 0.1 M PBS with 0.01% sodium azide at 4°C before further immunohistochemical processing.

Immunohistochemistry

Before cutting, the brain tissue was cryoprotected by immersion in 30% sucrose in 0.1 M PBS. Six series of 40 μm coronal sections were cut through the brain using a sliding microtome (Microm HM 440 E, Walldorf, Germany) equipped with an object table for freeze sectioning at -60°C.

Immunohistochemistry was performed using standard free-floating labeling procedures, and was carried out on a shaker table at room temperature.

Doublecortin staining. Immature neurons were visualized with anti-doublecortin antibody (polyclonal goat anti-doublecortin (C18: sc-8066, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) using one complete subseries of brain sections per animal with 240 μm distance between the sections. Doublecortin is a microtubule-associated protein that is exclusively found in somata and processes of migrating and differentiating neurons [63,64]. In short, after blocking the brain sections against endogenous peroxidase with 0.3% H2O2 in 0.1 M PBS for 30 minutes, the sections were pre-incubated with PBS-BT (0.1 M PBS with 0.1% Bovine Serum Albumin and 0.3% Triton-X-100) for 30 minutes. Brain sections were incubated overnight with polyclonal goat anti-doublecortin (1:3000 diluted in PBS-BT) as primary antibody. After incubating for 90 minutes with donkey anti-goat biotin secondary antibody (1:1500 diluted in PBS-BT, Jackson ImmunoResearch, West Grove, PA, USA), sections were transferred to a solution containing Vector ABC-elite (1:800 in PBS-BT; Vector Laboratories, Burlingame, CA, USA) for another 90 minutes. Visualization of doublecortin-positive cells was achieved by incubation with 0.02% 3,3’-diaminobenzidin tetra hydrochloride with 0.3% ammonium nickel sulphate as an intensifier in 0.05 M Tris buffer (DAB-Ni solution, pH = 7.6) with 0.006% H2O2 for 10 min. After washing with 0.1 M PBS, all stained sections were mounted on gelatin-coated slides (0.5% gelatin and 0.05% chrome-alum), dried overnight in a stove at 37°C, dehydrated in alcohol series, cleared with xylol and mounted in Entellan.

**Quantification.** Quantification of the doublecortin-positive newly formed immature neurons in the subgranular zone of the hippocampus was performed using a Zeiss Axioskop microscope equipped with hardware and software from Microbrightfield (Williston, VT, USA). Appropriate sections were digitized using a computer-assisted analysis system (Stereo Investigator). Three sections per animals were used at −70, −2.18 and −2.46 posterior to bregma, based on the mouse brain atlas of Franklin and Paxinos [65]. Contours were drawn along the borders of the hippocampus at 2.5× magnification and doublecortin-positive (Dcx+) cells were counted at 20× magnification. All quantifications were performed by two independent raters who were blind to the experiment groups. Measurements were averaged to obtain a single value per animal.

Biochemical analyses

**Serum and brain sterol analysis.** Serum cholesterol levels and the cholesterol precursor lathosterol and its oxidative brain specific metabolites, 24S-hydroxycholesterol and 27-hydroxycholesterol, were measured by gas-chromatography-mass-spectrometry-selected ionmonitoring (GC-MS-SIM) as described in detail previously [66–68]. Brains were homogenized and sterols were extracted overnight by chloroform/methanol trimethylsilylated prior to GC-MS-SIM analysis [66,67].

**Brain fatty acid analysis.** Fatty acid analyses were performed with a part of the brain homogenate (described above). Total lipid was extracted from brain homogenates by methanol and chloroform. Subsequently, samples were centrifuged at 3000 rpm for 10 min and the lower phase (chloroform and lipids) was removed. Chloroform was added to the upper phase, samples were centrifuged again at 3000 rpm for 10 min and the lower phase was combined with the first one. The chloroform fractions were dried in a SpeedVac® and 2 ml methanol and 40 μl concentrated sulfuric acid were added to the dried extract. The samples were heated at 100°C for 60 min, and 2 ml hexane and 0.5 ml 2.5 M sodium hydroxide solution were added. After vortexing and centrifuging the samples for 5 min at 3000 rpm, the upper layer was collected and evaporated in a SpeedVac®. The fatty acids (FAs) were dissolved in 125 μl iso-octane and analyzed on a GC-FID with a CP-SIL88 column (50 m x 0.25 mm id. 0.25 film thickness). The n6/n3 ratio was calculated as the sum of analyzed n6 FAs divided by the sum of n3 FA.
Quantitative real-time PCR (qRT-PCR). A part of the frozen brain tissue, including both hippocampi, were collected in 1 ml cold Trizol (Invitrogen, Paisley, UK) and homogenized by sonication. After chloroform extraction and isopropyl alcohol precipitation, RNA was dissolved in 25 μl RNase-free DEPC-treated water. The RNA concentrations were measured with a Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE, USA). cDNA synthesis was performed using 1 μg RNA dissolved in 10 μl RNase-free DEPC-treated water containing 2 μl 5 × iScript reaction mix and 0.5 μl iScript reverse transcriptase (iScript cDNA synthesis kit, Bio-Rad Laboratories B.V., Veenendaal, The Netherlands) at 25°C for 5 min, at 42°C for 30 min and at 85°C for 5 min (Eppendorf Thermoblock Mastercycler 5330).

Quantitative real-time PCR (qRT-PCR) was performed in a total volume of 10 μl buffer solution containing 2 μl of template cDNA, 5 μl 2× SYBR Green Master mix (Applied Biosystems, Foster City, CA, USA), 2.92 μl RNase-free DEPC-treated water and 0.04 μl of each primer (100 μM); Primers for cluster of differentiation 36 (CD36), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), interleukin-1β (IL-1β), interleukin-6 (IL-6), monocyte chemotactic protein 1 (MCP-1) and tumor necrosis factor-α (TNF-α) were designed using Vector Primer Express software: (Applied Biosystems). Primer pairs were as follows: CD36: 5'-ATGGGCTGTATCGAGAAGTC-3' and 5'-GTCCTTCCCAATAGCATGCTCC-3'; GAPDH: 5'-AGGTTGCTTGTAGAAGATTGTTGCTC-3'; IL-1β: 5'-GGAACTGTGTTCTGAACTACT-3' and 5'-ATCCTTTTGGGTTCGTCACT-3'; IL-6: 5'-CAAGTGCAGGCCTAAAATACACAGT-3' and 5'-ATGCCATTGCA-CACCTTTTCT-3'; MCP-1: 5'-CCCAATGATGGACTGCT-GAGA-3' and 5'-TCTGGACCACATCTCTTCTG-3'; and TNF-α: 5'-CAGACCCCTTACACTGATCATCT-3' and 5'-CCTCCACTGTGCTCTTGTGA-3'. The optimal temperature protocol was determined to be 95°C for 10 min followed by 40 reaction cycles at 90°C for 15 s and at 60°C for 1 min, using a StepOnePlus real time PCR system (Applied Biosystems, Foster City, CA, USA). The absolute quantities were determined using standard curves, and the validity of the results was checked by running appropriate negative controls. The quantity of cDNA was calculated for each sample with StepOne software version 2.2.2. Relative gene expression ratios, calculated

Statistical analysis

Data are expressed as mean ± SEM and were analyzed with SPSS for windows 18.0 software (SPSS Inc. Chicago, IL, USA). The repeated measures ANOVA was used for the acquisition phase of the MWM and rMWM (with the repeated measure: trial block), followed by a Bonferroni post hoc to analyze possible interactions between trial block, genotype and/or diet. If interactions between trial block, genotype and/or diet (between-group-factors) were present, the data were split for the concerning factor and thereafter analyzed again with the MANOVA. If no interactions between the genotype and diet were present and overall analysis revealed a significant effect of diet, the separate diet groups were analyzed post hoc by using Tukey’s HSD test. For clarity reasons, F-values are not displayed. Furthermore, only between-group interactions that reached statistical significance are specified in detail. Statistical significance was set at p<0.05.

Results

Body and brain weight

All mice were weighed one week before starting the behavioral test battery and again on the day of the MR measurements (1–2 months later). Since body weights within the groups did not change significantly between those two time points (ANOVA, p>0.50), the mean weight was used for further statistical analyses. Body weight was affected by genotype (ANOVA, p<0.001), but not by dietary intake (ANOVA, p=0.913). No significant genotype x diet interaction was observed (ANOVA, p=0.164). Overall mean body weight was 39.6±0.7 g in the AβPP-PS1 mice and 35.2±0.6 g in the wild-type mice. Absolute brain weight was not affected by genotype (ANOVA, p=0.733) or by diet (ANOVA, p=0.543). No significant genotype x diet interaction was observed (ANOVA, p=0.078). Overall mean brain weight was 0.53±0.00 g in AβPP-PS1 animals and 0.53±0.01 g in wild-type mice.

Behavioral analyses

Open field

In the open field, locomotor activity and active exploration parameters (walking, sitting, wall leaning, rearing) and grooming were scored for 30 minutes. In addition, total walking distance, mean walking velocity, and the time spent in the corners respectively the center of the open field were obtained from the recorded sessions. AβPP-PS1 mice were more active in the open field than wild-type mice, independent of diet (genotype x diet interaction, walking p=0.777; sitting p=0.857; distance moved p=0.926; velocity p=0.927). AβPP-PS1 mice walked more (Figure 2A; ANOVA p=0.015) and sat less (Figure 2B; ANOVA p<0.001) than wild-type mice. This resulted in an increased distance moved (Figure 2F; ANOVA p<0.001) and higher mean walking speed in AβPP-PS1 mice compared to wild-type animals (ANOVA p<0.001; wild-type mice 4.2±0.1 cm/s, AβPP-PS1 5.1±0.3 cm/s). Dietary intake affected the time spent sitting (ANOVA, p=0.013), the distance moved (ANOVA, p=0.006) and the mean velocity (ANOVA, p=0.006). Dietary intervention with the FC diet had no effect on these parameters (post hoc, p>0.05). However, animals fed the DEU diet sat less than animals fed the CO diet (Figure 2B; post hoc p=0.025), but did not differ from the mice fed the FC diet (post hoc p=0.322). Furthermore, mice fed the DEU diet also traveled a greater distance (Figure 2F; post hoc p=0.009) with a higher mean velocity (post hoc p=0.009; CO diet 4.2±0.2 cm/s, DEU diet 5.1±0.3 cm/s, FC diet 4.5±0.2 cm/s) than animals fed the CO diet, but again did not differ from the animals fed the FC diet (post hoc, p=0.098). Overall analysis revealed a tendency for a diet effect on the time spent walking (p=0.053), but since this did not reach statistical significance, no additional post hoc tests were performed to compare the different diet groups.
Moreover, AβPP-PS1 mice displayed less explorative behavior away from the walls of the open field, e.g. rearing (Figure 2C; ANOVA p = 0.030) compared to wild-type animals, but more explorative behavior against the walls of the open field, e.g. wall leaning (Figure 2D; ANOVA p < 0.001), independent of diet (genotype x diet interaction, rearing p = 0.468; wall leaning p = 0.513). Rearing behavior was not affected by dietary intervention with the DEU and FC diets (ANOVA, p = 0.355). Wall leaning behavior however was affected by diet (ANOVA, p = 0.001). Animals fed the DEU diet leaned more against the walls of the open field than mice fed the FC diet (Figure 2D; post hoc p = 0.007), and also slightly more than animals fed the CO diet (post hoc, p = 0.070), although this did not reach statistical significance. No significant differences between wild-type and AβPP-PS1 mice (Figure 2E; ANOVA p = 0.744) nor between the dietary groups (ANOVA, p = 0.620) were observed for grooming behavior (genotype x diet interaction, p = 0.172).

Furthermore, AβPP-PS1 mice spent slightly less time in the center of the open field than wild-type mice (Figure 2G; ANOVA p = 0.064), although it did not reach statistical significance. No differences were observed between the dietary groups in the time spent in the center of the open field (ANOVA, p = 0.116). No genotype x diet interaction was observed for the time spent in the center of the open field (p = 0.356). AβPP-PS1 mice did however spend significantly more time in the corners of the open field compared to wild-type animals (Figure 2H; ANOVA p = 0.001), independent of diet (genotype x diet interaction, p = 0.085). Dietary intake affected the time spent in the corners of the open field (ANOVA, p = 0.007), such that animals fed the FC diet spent significantly less time in the corners of the open field than mice fed the CO diet (post hoc, p = 0.038) and the DEU diet (post hoc, p = 0.033).

Altogether these data show increased activity, but decreased explorative behavior in AβPP-PS1 mice. Furthermore, AβPP-PS1 mice also display increased anxiety-related behavior, as indicated by the increased time spent wall leaning and increased time spent in the corners of the open field [58,70]. Dietary intervention with the DEU diet increased general locomotor activity and anxiety-related exploration (e.g. wall leaning) in wild-type and AβPP-PS1 mice. Our results might suggest that the FC diet could have an anxiolytic effect, since it decreased the time spent in the corners of the open field in both wild-type and AβPP-PS1 mice.

Morrис water maze (MWM). The Morris water maze is designed to test spatial learning by training the mice to find a hidden platform (acquisition phase) in a pool. Spatial memory is tested in a trial in which the platform is removed from the maze (probe trial) following the last trial of the acquisition phase.

Both AβPP-PS1 and wild-type mice showed a decrease in escape latency during training (Figure 3A; ANOVA p < 0.001). No significant time x genotype, time x diet or time x genotype x diet interactions were observed (p > 0.05), indicating that all animals learned the position of the hidden platform equally well. However, escape latencies were significantly higher in AβPP-PS1 mice compared to wild-type animals (Figure 3A; ANOVA p < 0.001), independent of dietary intake (genotype x diet interaction, p = 0.097), indicating that spatial learning was affected by genotype. Escape latencies did not differ between the animals fed the CO diet, DEU diet or FC diet (Figure 3B; ANOVA p = 0.205). During acquisition training, swim speed decreased in both AβPP-PS1 and wild-type mice over time (data not shown; ANOVA p < 0.001). No significant time x genotype, time x diet or time x genotype x diet interactions were observed (p > 0.05). However, the average swim speed was significantly higher in AβPP-PS1 mice compared to wild-type animals during training (ANOVA p = 0.001; wild-type 10.5 ± 0.3 cm/s; AβPP-PS1 12.5 ± 0.5 cm/s), independent of dietary intake (genotype x diet interaction p = 0.652). The mean swim speed did not differ (ANOVA, p = 0.341) between the animals fed the CO diet (11.3 ± 0.4 cm/s), DEU diet (10.6 ± 0.4 cm/s) or FC diet (11.5 ± 0.6 cm/s).

During the probe trial, AβPP-PS1 mice spent less time in the target NE quadrant (Figure 3C, ANOVA p = 0.033) than wild-type mice, independent of diet (genotype x diet interaction, p = 0.689), indicating impaired spatial memory. Furthermore, AβPP-PS1 mice also spent less time in the exact area where the platform had been located (Figure 3D; ANOVA p = 0.010) and had a higher latency to reach the former platform location (Figure 3E; ANOVA p = 0.003) than wild-type animals, independent of diet, again reflecting impaired spatial memory. Dietary intervention with DEU and FC had no effect on these parameters of spatial memory (ANOVA, p > 0.05). Overall statistical analysis indicated significant genotype x diet interactions for the swim distance (p = 0.004) and mean velocity (p = 0.004).

Dietary intake affected the swim distance (ANOVA, p = 0.014) and mean velocity (ANOVA, p = 0.015) in AβPP-PS1 mice, such that AβPP-PS1 mice on the FC diet displayed a shorter swim distance (Figure 3F; post hoc p = 0.013) and lower mean swim velocity than the AβPP-PS1 animals on CO diet (post hoc, p = 0.015; AβPP-PS1-CO diet 17.3 ± 0.4 cm/s, AβPP-PS1-FC diet 13.8 ± 1.2 cm/s), and compared to the wild-type animals on FC diet (ANOVA, p = 0.009; wild-type-FC diet 16.9 ± 0.4 cm/s), but not compared to the AβPP-PS1 animals on DEU diet (post hoc, p = 0.079; AβPP-PS1-DEU diet 16.8 ± 0.9 cm/s).

Reverse Morris water maze (rMWM). In the reverse Morris water maze (rMWM), mice have to learn to find a novel position for the hidden platform. This task is considered to be a test for new learning abilities, in which a previous successful strategy must be inhibited and a new strategy should be developed.

Both AβPP-PS1 and wild-type mice showed a decrease in escape latency during training (Figure 4A; ANOVA p = 0.016). No significant time x genotype, time x diet or time x genotype x diet interactions were observed (p > 0.05), indicating that all animals learned the new platform position equally well. Escape latencies did not differ between AβPP-PS1 and wild-type mice (Figure 4A; ANOVA p = 0.160), nor did they differ between the animals on CO diet, DEU diet and FC diet (Figure 4B; ANOVA p = 0.274). No genotype x diet interaction was observed for the escape latencies (p = 0.922).

During acquisition training with a new platform location, swim speed decreased in both AβPP-PS1 and wild-type mice over time (data not shown; ANOVA p < 0.001). No significant time x genotype, time x diet or time x genotype x diet interactions were observed (p > 0.05). However, the average swim speed was significantly higher in AβPP-PS1 mice compared to wild-type animals during rMWM training (ANOVA p = 0.008; wild-type 5.7 ± 0.2 cm/s; AβPP-PS1 6.8 ± 0.4 cm/s), independent of dietary intake (genotype x diet interaction p = 0.827). The mean swim speed did not differ (ANOVA, p = 0.511) between the animals fed the CO diet (5.9 ± 0.3 cm/s), DEU diet (6.5 ± 0.4 cm/s) or FC diet (6.0 ± 0.4 cm/s).

During the probe trial, AβPP-PS1 mice spent less time in the target SW quadrant (Figure 4C; ANOVA p = 0.006) than wild-type mice, independent of diet (genotype x diet interaction, p = 0.120), although all animals performed well above 25% chance level, indicating good memorization of the platform quadrant. However, AβPP-PS1 mice also spent less time in the exact area where the platform had been located after relocation (Figure 4D; ANOVA p < 0.001), indicating impaired spatial memory. Furthermore, they displayed a slightly higher latency to reach the former
platform location than wild-type animals (Figure 4E; ANOVA p = 0.054), although this did not reach statistical significance. Dietary intervention with DEU and FC had no effect on these parameters of spatial memory (ANOVA, p > 0.05). No differences were observed between AβPP-PS1 and wild-type animals in the swim distance (Figure 4F; ANOVA p = 0.909) or in the mean swim velocity (ANOVA p = 0.918; wild-type 16.3 ± 0.2 cm/s, AβPP-PS1 16.2 ± 0.4 cm/s). Overall statistical analysis indicated a significant

Figure 2. Open field behavior of 11-month-old AβPP-PS1 and wild-type mice on control and specific multi-nutrient diets. Open field parameters were measured within a 30 min period. A: AβPP-PS1 mice spent more time walking than wild-type mice (*p = 0.015). Walking was not affected by dietary intake. B: AβPP-PS1 mice spent less time sitting than wild-type mice (*p < 0.001). Animals on the DHA, EPA and UMP (DEU) diet sat let than animals on control (CO) diet (*p = 0.025), but did not differ from the mice on the Fortasyn® Connect (FC) diet. C: AβPP-PS1 mice spent less time rearing than wild-type mice (p = 0.030). Rearing behavior was not affected by dietary intake. D: AβPP-PS1 mice spent more time wall leaning than wild-type mice (*p < 0.001). Animals fed the DEU diet leaned more against the walls than mice fed the FC diet (*p = 0.007), and also slightly more than animals fed the CO diet (a*p = 0.070), although this did not reach statistical significance. E: Grooming behavior was similar among wild-type and AβPP-PS1 mice, and was not affected by dietary intake. F: AβPP-PS1 mice traveled a longer distance than wild-type mice (*p < 0.001). Mice fed the DEU diet traveled a greater distance than animals fed the CO diet (a*p = 0.009), but did not differ from the animals fed the FC diet. G: AβPP-PS1 mice spent slightly less time in the center of the open field compared to wild-type mice (*p = 0.001). Animals fed the FC diet spent less time in the corners of the open field than mice fed the CO diet (a*p = 0.038) and animals fed the DEU diet (b*p = 0.033).

doi:10.1371/journal.pone.0075393.g002
effect of diet on swim distance (ANOVA, \(p = 0.030\)) and mean swim velocity (ANOVA \(p = 0.031\); CO diet 16.6 ± 0.3 cm/s, DEU diet 16.5 ± 0.3 cm/s, FC diet 15.6 ± 0.5 cm/s). However, Tukey's post hoc analysis revealed no significant differences between any of the diet groups (post hoc, \(p > 0.1\)).

Magnetic resonance imaging (MRI)
Magnetic resonance spectroscopy (MRS). To determine hippocampal metabolite concentrations, single voxel \(^1\)H MRS at 11.7 T was used (Figure 5). No differences were observed between wild-type and AβPP-PS1 mice (Figure 5A), nor between the different diet groups (Figure 5B) in the levels of creatine and phosphocreatine (tCre; ANOVA \(p > 0.05\)). Therefore, tissue concentrations of metabolites are given relative to tCre as applied by others [71,72].

AβPP-PS1 mice had significantly lower levels of N-acetylaspartate and N-acetylaspartylglutamate (tNAA; ANOVA \(p = 0.030\)) than wild-type mice, independent of diet (genotype × diet interaction, \(p = 0.513\), indicating decreased neuronal integrity (Figure 5A). Wild-type and AβPP-PS1 mice had similar levels of choline-containing compounds (tCho; ANOVA \(p = 0.079\)), glutamine and glutamate (Glx; ANOVA \(p = 0.963\), myo-Inositol and glycine (mI+Gly; ANOVA \(p = 0.196\)) and taurine (Tau; ANOVA \(p = 0.475\)).

Statistical analysis indicated a significant effect of dietary intake on tCho levels, independent of genotype (Figure 5B; ANOVA \(p = 0.035\)). Post hoc analysis revealed that animals fed the FC diet

Figure 3. Morris water maze performance of 11-month-old AβPP-PS1 and wild-type mice on control and multi-nutrient diets. Spatial learning was measured in a 4-day acquisition phase, by determining the latency to find a hidden platform in the NE quadrant. Spatial memory was tested in the probe phase in which the percentage of time spent in the target NE quadrant, the time spent in the former platform area, the latency to the former platform area and the total distance moved were measured. A: Both AβPP-PS1 and wild-type mice showed a decrease in latency during training. Overall escape latencies were higher in AβPP-PS1 mice (*p < 0.001), independent of dietary intake. B: Animals on control (CO), the DHA, EPA and UMP (DEU) and Fortasyn® Connect (FC) diets showed a similar decrease in latency during training, independent of genotype. Overall escape latencies were not affected by dietary intake. C: AβPP-PS1 mice spent less time in the target NE quadrant than wild-type mice, independent of dietary intake (*p = 0.033). Time spent in the NE quadrant was unaffected by dietary intake. D: AβPP-PS1 mice spent less time in the former platform area than wild-type mice (*p = 0.010), independent of dietary intake. Time spent in the exact former platform area was unaffected by dietary intake. E: AβPP-PS1 mice had a higher latency to reach the former platform location than wild-type mice (*p = 0.003), independent of dietary intake. Latency to reach the former platform location was unaffected by dietary intake. F: AβPP-PS1 mice on FC diet displayed a shorter swim distance compared to wild-type mice on FC diet (*p = 0.009) and compared to AβPP-PS1 mice on CO diet (*p = 0.013), but not compared to AβPP-PS1 mice on DEU diet. doi:10.1371/journal.pone.0075393.g003
had significant lower tCho levels than animals fed the CO diet (post hoc, $p = 0.039$), but no difference compared to the animals fed the DEU diet (post hoc, $p = 0.228$). No differences were observed between the different diets in relative concentrations of Glx (ANOVA, $p = 0.627$), mI+Gly (ANOVA, $p = 0.400$), tNAA (ANOVA, $p = 0.156$) and Tau (ANOVA, $p = 0.523$).

Immunohistochemistry

Doublecortin staining. Immature neurons were visualized with a polyclonal antibody against doublecortin. Doublecortin-positive (Dcx+) cells were counted in three alternating hippocampal sections as a measure for neurogenesis.

Overall statistical analysis indicated a significant genotype×diet interaction (ANOVA, $p = 0.004$) for the relative amount of Dcx+ cells. In wild-type animals, the relative amount of Dcx+ cells were similar for all diet groups (ANOVA, $p = 0.530$). However, in AβPP-PS1 mice, the relative amount of Dcx+ cells was affected by dietary intake (ANOVA, $p = 0.017$). Post hoc analysis revealed that AβPP-PS1 mice on CO diet showed a decreased amount of Dcx+ cells compared to wild-type mice on CO diet (Figure 6; ANOVA, $p = 0.004$), indicating decreased neurogenesis in AβPP-PS1 mice on a normal control diet. Moreover, AβPP-PS1 mice fed the FC diet had a significantly higher relative amount of Dcx+ cells than AβPP-PS1 animals fed the CO diet (post hoc, $p = 0.015$), suggesting that the FC diet restored neurogenesis in AβPP-PS1.
Figure 5. Hippocampal neurochemical profile of 12-month-old AβPP-PS1 and wild-type mice on control and specific multi-nutrient diets. The neurochemical profile of the hippocampus was determined with single voxel 1H MRS at 11.7 Tesla. A: AβPP-PS1 mice showed a significant decrease in tCho/tCre compared to wild-type mice (*p = 0.030), independent of dietary intake. AβPP-PS1 and wild-type mice displayed similar levels of tCho/tCre, tCre, Glx/tCre, m+Gly/tCre and Tau/tCre. B: Both wild-type and AβPP-PS1 mice fed the Fortasyn® Connect (FC) diet showed a significant decrease in tCho/tCre levels compared to animals fed the control (CO) diet (*p = 0.039), but no difference compared to mice fed the DHA, EPA and UMP (DEU) diet. Dietary intake did not affect the levels of tCre, Glx/tCre, m+Gly/tCre, tNAA/tCre and Tau/tCre. Values represent the mean and SEM. tCho = choline-containing compounds; τtCre = creatine and phosphocreatine; Glx = glutamine and glutamate; Glx = glutamate and glutamine; m+Gly = myo-inositol and glycine; tNAA = N-acetylaspartate and N-acetylaspartylglutamate; Tau = taurine.

doi:10.1371/journal.pone.0075393.g005

Figure 6. Neurogenesis in 12-month-old AβPP-PS1 and wild-type mice on control and specific multi-nutrient diets. From 2 months of age, mice were fed either a control (CO), a DHA, EPA and UMP (DEU) or a Fortasyn® Connect (FC) diet. The amount of immature neurons in the subgranular zone of the hippocampus was visualized immunohistochemically with a polyclonal goat anti-doublecortin antibody (1:3000) as a measure for neurogenesis. Values represent the mean and SEM and are relative (%) compared to wild-type mice on the CO diet. In wild-type animals, the relative amount of doublecortin-positive (Dcx+) immature neurons was similar for all diet groups. However, in AβPP-PS1 mice the relative amount of Dcx+ immature neurons was affected by dietary intake (p = 0.017). Post hoc analysis revealed that AβPP-PS1 mice fed the CO diet displayed a significantly decreased relative amount of Dcx+ immature neurons compared to wild-type mice on the CO diet (*p = 0.004). The FC diet significantly increased the relative amount of Dcx+ immature neurons in AβPP-PS1 mice as compared to AβPP-PS1 mice on CO diet (*p = 0.015). Furthermore, AβPP-PS1 mice on the FC diet had slightly higher relative amount of Dcx+ immature neurons than wild-type animals on the FC diet (*p = 0.053), although this did not reach statistical significance.

doi:10.1371/journal.pone.0075393.g006

Biochemical analyses

Serum and brain sterol analysis. Brain cholesterol levels (Figure 7A) were similar between wild-type and AβPP-PS1 mice (ANOVA, p = 0.369), and between the diet groups (ANOVA, p = 0.637). However, dietary intervention significantly affected serum cholesterol levels (Figure 7B) in wild-type mice (ANOVA, p < 0.001), but not in AβPP-PS1 mice (ANOVA, p = 0.314), as indicated by a significant genotype x diet interaction (p = 0.009). Post hoc analysis revealed that in wild-type mice the DEU diet decreased serum cholesterol levels compared to the CO diet (post hoc, p = 0.014), and the FC diet decreased serum cholesterol levels further (post hoc, p < 0.001 compared to CO diet and p = 0.026 compared to DEU diet). No genotype effects on serum cholesterol levels were observed between the wild-type and AβPP-PS1 mice on CO (ANOVA, p = 0.101) and DEU diets (ANOVA, p = 0.353), but AβPP-PS1 mice on FC diet had significantly higher serum cholesterol levels than wild-type mice on FC diet (ANOVA, p = 0.007).

In addition, brain levels of lathosterol (Figure 7C), a main cholesterol precursor in the “de novo” synthesis pathway, were similar between wild-type and AβPP-PS1 mice (ANOVA, p = 0.800). Dietary intake did affect the brain levels of lathosterol (ANOVA, p = 0.003), such that animals fed the DEU (post hoc, p = 0.003) and FC diets (post hoc, p = 0.010) displayed significantly decreased levels of brain lathosterol compared to animals fed the CO diet, independent of genotype (genotype x diet interaction, p = 0.088). Serum lathosterol levels (Figure 7D) were similar...
between wild-type and AβPP-PS1 mice (ANOVA, \(p = 0.609\)), and between the diet groups (ANOVA, \(p = 0.709\)).

Furthermore, the levels of cholesterol's brain specific oxidative metabolite 24S-hydroxycholesterol did not differ significantly in the brains (ANOVA, \(p = 0.072\)) and sera (ANOVA, \(p = 0.510\)) of
wild-type and AβPP-PS1 mice. Dietary intake did affect both brain (ANOVA, $p<0.001$) and serum (ANOVA, $p=0.001$) 24S-hydroxycholesterol levels, such that animals fed the DEU (post hoc, $p=0.004$) and FC diets (post hoc, $p<0.001$) had significantly higher levels of 24S-hydroxycholesterol in the brain compared to animals fed the CO diet (Figure 7E), independent of genotype (genotype × diet interaction, $p=0.054$), indicating increased conversion of cholesterol in the brain due to dietary intervention. In contrast, serum 24S-hydroxycholesterol levels (Figure 7F) were decreased in animals fed the DEU (post hoc, $p=0.028$) and FC diets (post hoc, $p<0.001$) compared to animals fed the CO diet, independent of genotype (genotype × diet interaction, $p=0.477$).

Another oxidative metabolite of cholesterol, 27-hydroxycholesterol (Figure 7G), was significantly decreased in the brains of AβPP-PS1 mice compared to wild-type animals (ANOVA, $p=0.040$), independent of diet (genotype × diet interaction, $p=0.817$), suggesting a decreased flux of cholesterol from the periphery into the brain [73-75]. No significant differences could be observed in the levels of brain 27-hydroxycholesterol between the diet groups (ANOVA, $p=0.073$). Serum 27-hydroxycholesterol levels (Figure 7H) were similar between wild-type and AβPP-PS1 mice (ANOVA, $p=0.256$). Overall analysis revealed a tendency for an effect of diet intervention (ANOVA, $p=0.054$) on serum 27-hydroxycholesterol levels, but this did not reach statistical significance.

### Brain fatty acid analysis

Dietary intake affected the relative concentrations of oleic acid (ANOVA, $p=0.011$), arachidonic acid (ANOVA, $p<0.001$), docosahexaenoic acid (ANOVA, $p<0.001$), omega-3 fatty acids (n3 FAs; ANOVA $p<0.001$), and omega-6 FAs (ANOVA; $p<0.001$) in both wild-type and AβPP-PS1 mice (Figure 8). Animals fed the DEU and FC diets (post hoc $p<0.001$) showed a shift in the balance between n3 and n6 fatty acids as compared to animals fed the CO diet (main ANOVA diet effect, $p<0.001$). The relative amount of n3 FA in DEU and FC fed mice increased compared to the CO diet (post hoc, $p<0.001$), whereas the relative amount of n6 decreased (post hoc, $p<0.001$), resulting in a pronounced shift in the n3/n6 ratio in DEU and FC fed mice in favor of the n3 FA. The reduction of the relative n6 content was mainly caused by a relative decrease in arachidonic acid (AA; C20:4n6; post hoc $p<0.001$), while the higher n3 content originated from a relative increase in DHA (C22:6n3; post hoc $p<0.001$) in both the DEU and FC fed animals as compared to the CO fed animals. Furthermore, the relative concentration of oleic acid (OA; C18:1n9) was significantly increased in the DEU fed mice (post hoc, $p=0.005$), and also slightly increased in the FC fed animals (post hoc, $p=0.066$) as compared to the CO diet, although it did not reach statistical significance.

No significant differences were observed between the DEU and FC diets in any fatty acid analyzed (post hoc, $p>0.05$). The relative amounts of palmitic acid (C16:0; ANOVA $p=0.714$), stearic acid (C18:0; ANOVA $p=0.041$), total saturated fatty acids (SFA; ANOVA $p=0.793$), total mono-unsaturated fatty acids (MUFA; ANOVA $p=0.316$) and total poly-unsaturated fatty acids (PUFA; ANOVA $p=0.459$) were unaffected by the diets (data not shown).

No significant genotype effects or genotype × diet interactions were found for any of the fatty acids analyzed (ANOVA, $p>0.05$).

### Quantitative real-time PCR (qRT-PCR)

Wild-type and AβPP-PS1 mice displayed similar levels of MCP-1 (ANOVA, $p=0.927$), IL-6 (ANOVA, $p=0.081$), TNF-α (ANOVA, $p=0.701$) and CD36 (ANOVA, $p=0.180$). However, IL-1β levels were significantly increased in AβPP-PS1 mice compared to wild-type animals (Figure 9A; ANOVA, $p<0.001$), independent of dietary intake (genotype × diet interaction, $p=0.272$). Furthermore, statistical analysis indicated a significant effect of dietary intake on the levels of IL-1β (ANOVA, $p=0.005$). Post hoc analysis revealed that both wild-type and AβPP-PS1 animals fed the DEU (post hoc, $p=0.034$) and FC diets (post hoc, $p=0.013$) had significantly higher levels of IL-1β than animals fed the CO diet (Figure 9B). No differences were observed between the different diets in the levels of MCP-1 (ANOVA, $p=0.349$), IL-6 (ANOVA, $p=0.232$), TNF-α (ANOVA, $p=0.707$) and CD36 (ANOVA, $p=0.157$).

### Discussion

In the present study, we investigated the extent to which long-term consumption of two specific multi-nutrient enriched diets, developed to support membrane synthesis and maintenance, can modulate behavior, cognition, hippocampal metabolic levels, neurogenesis and inflammation in 11-12-month-old AβPP-PS1 mice. An overview of the main results found in the current study is shown in Table 3.

In agreement with previous results from our lab [58,76], 11-month-old AβPP-PS1 mice displayed increased activity and anxiety-related behavior, and decreased explorative behavior in

---

Figure 8. Brain fatty acids in 12-month-old AβPP-PS1 and wild-type mice on control and specific multi-nutrient diets. The relative concentrations of different fatty acids were determined in the lipid fraction of brain homogenates, and were similar between AβPP-PS1 and wild-type mice. Dietary intake affected the relative concentrations of different fatty acids similarly in AβPP-PS1 and wild-type mice. Both the DHA, EPA and UMP (DEU) diet and the Fortasyn® Connect (FC) diet increased the relative concentrations of omega-3 fatty acids (n3) and decreased the relative concentrations of omega-6 fatty acids (n6), resulting in a pronounced shift in the n3/n6 ratio in DEU and FC fed mice in favor of the n3 FA. The reduction of the relative n6 content was mainly caused by a relative decrease in arachidonic acid (AA; C20:4n6; post hoc $p<0.001$), while the higher n3 content originated from a relative increase in DHA (C22:6n3; post hoc $p<0.001$) in both the DEU and FC fed animals as compared to the CO fed animals. Furthermore, the relative concentration of oleic acid (OA; C18:1n9) was significantly increased in the DEU fed mice (post hoc, $p=0.005$), and also slightly increased in the FC fed animals (post hoc, $p=0.066$) as compared to the CO diet, although it did not reach statistical significance.

No significant differences were observed between the DEU and FC diets in any fatty acid analyzed (post hoc, $p>0.05$). The relative amounts of palmitic acid (C16:0; ANOVA $p=0.714$), stearic acid (C18:0; ANOVA $p=0.041$), total saturated fatty acids (SFA; ANOVA $p=0.793$), total mono-unsaturated fatty acids (MUFA; ANOVA $p=0.316$) and total poly-unsaturated fatty acids (PUFA; ANOVA $p=0.459$) were unaffected by the diets (data not shown).

No significant genotype effects or genotype × diet interactions were found for any of the fatty acids analyzed (ANOVA, $p>0.05$).

Diet Effect on AD Mice Brain Structure & Function

PLOS ONE | www.plosone.org 13 September 2013 | Volume 8 | Issue 9 | e75393

doi:10.1371/journal.pone.0075393.g008

---

**Figure 8. Brain fatty acids in 12-month-old AβPP-PS1 and wild-type mice on control and specific multi-nutrient diets.** The relative concentrations of different fatty acids were determined in the lipid fraction of brain homogenates, and were similar between AβPP-PS1 and wild-type mice. Diet Effect on AD Mice Brain Structure & Function

PLOS ONE | www.plosone.org 13 September 2013 | Volume 8 | Issue 9 | e75393

doi:10.1371/journal.pone.0075393.g008
the open field as compared to age-matched wild-type mice. Hyperactivity and decreased explorative behavior are specific characteristics of many AβPP transgenic mice [77–79] and may be explained as a result of elevated anxiety levels [80,81]. Curiosity motivates mice to explore a novel environment, but this exploratory drive is in conflict with fear of the unknown. Hyperactivity and anxiety-related behavior in AβPP transgenic mice resemble anxiety symptoms and restlessness, which occur in up to 70% of AD patients during the course of their illness and are significantly correlated with impairments in activities of daily living [82–84]. Dietary intervention with the DEU and FC diets differentially affected open field behavior in both AβPP-PS1 and wild-type mice. While the DEU diet increased general locomotor activity (restlessness) and anxiety-related exploration (e.g. wall leaning), our results suggest that the FC diet could have an anxiolytic effect, since it decreased the time spent in the corners of the open field as compared to the animals on CO and DEU diets. Previous studies have shown that rats fed an n3 lc-PUFA deficient diet display increased anxiety-related behavior in the open field and elevated plus maze tasks as compared to animals fed an n3 lc-PUFA adequate diet [85,86]. Supplementation with n3 lc-PUFAs led to substantial reduction in the anxiety levels of n3 lc-PUFA deficient rats [86,87] and mice [88]. Moreover, n3 fatty acid deficiency has been linked to increased vulnerability to stress, elevated aggression, and increased depressive-like symptoms in rodents [89]. Supplementation with n3 lc-PUFAs has also shown beneficial effects on depressive symptoms and agitation in patients with mild to moderate AD [90]. However, it should be noted that both the DEU diet and the FC diet contained equal amounts of n3 lc-PUFAs, suggesting that the combination of additional nutrients in the FC diet was important for the efficacy on anxiety-related behavior. Interestingly, Schipper et al. showed that a combination of n3 lc-PUFAs, phospholipids and B-vitamins (which are also part of the current FC diet) completely abolished anxiety-related behavioral responses, increased social behavior and facilitated fear extinction recall in serotonin transporter knockout (SERT-ko) rats [91]. Furthermore, the FC diet also reduced anxiety-related behavior in the open field in 12-month-old apolipoprotein E (apoE)-deficient mice [92]. Combined, these results suggest that supplementation with the FC diet could potentially be beneficial for several neurodegenerative and neurological disorders in which patients exhibit symptoms of agitation, anxiety and depression.

In line with our previous results [58,76], 11-month-old AβPP-PS1 mice also showed impaired performance in the MWM and rMWM as compared to age-matched wild-type animals. Although both AβPP-PS1 and wild-type mice showed a similar decrease in escape latency during training in the MWM, overall escape latencies were significantly higher in AβPP-PS1 mice, independent of dietary intake. Longer escape latencies during spatial navigation can be caused by slower swim speed, although this is not a confounding factor in the current study, since AβPP-PS1 mice displayed higher swim speeds during the task acquisition trials. Longer escape latencies during spatial navigation may also be caused by the use of certain, less efficient, search strategies, such as a constant random search of the entire surface area of the pool, which would indicate a complete lack of spatial learning abilities, or by persistent performance of a less efficient than spatial (direct)
search strategy, such as circling the pool at a certain distance from the wall to find the platform [93,94]. In this strategy, mice have not used the spatial cues to learn the location of the platform, although such a strategy would result in a successful location of the escape platform during training. Since AβPP-PS1 mice searched the target NE quadrant during the probe trial at chance level (25% or less), our results might imply that the AβPP-PS1 mice made use of a random or a persistent non-spatial search strategy to locate the platform during acquisition training. This is in line with a study by O’Leary and Brown, in which the search strategies used by 16-month-old AβPP-PS1 and wild-type mice during visuo-spatial navigation in the Barnes Maze were analyzed [95]. 16-month-old AβPP-PS1 mice predominantly made use of a random search strategy to locate the escape hole in the Barnes Maze, whereas wild-type mice predominantly made use of a spatial (direct and accurate) search strategy. Similar results have been found for the

search strategies used by the TgCRND8 transgenic AβPP mouse model in the MWM test [96,97]. Moreover, it was shown that C57BL6 mice, treated with Temozolomide (TMZ) to suppress adult hippocampal neurogenesis, displayed a delayed (or even absent) use of directed and place specific search patterns in the (reversal) MWM test compared to untreated mice, suggesting that hippocampal neurogenesis is necessary for adding flexibility to some hippocampus-dependent qualitative parameters of learning [93]. Consistent with our current findings, reduced hippocampal neurogenesis has been found previously in AβPP-PS1 mice [98–100] and in AD patients [101,102], and might underlie some aspects of the cognitive deficits in AD.

In line with our previous findings [76], AβPP-PS1 and wild-type mice showed a similar decrease in escape latency during training in the reversal MWM. The reversal task requires selective memory retrieval of the newly learned location of the platform, and

| Table 3. Overview of the main genotype and diet effects found in the current study. |
|------------------------------------|--------------------------------|-----------------|
| Effects of genotype:              | Compared to wild-type mice    | AβPP-PS1 mice   |
| Open field Behavior & activity    | Increased activity & anxiety-related behavior | Decreased exploration |
| Morris water maze Learning & memory | Decreased learning & memory | |
| reverse MWM Learning & memory     | Decreased memory              | |
| Hippocampal 1H MRS Metabolite levels | Decreased tNAA/tCre | |
| Immature neurons Hippocampus      | Decreased neurogenesis         | |
| Sterol analyses Serum             | n.s.                          | |
| Fatty acid analysis Brain         | Decreased 27-hydroxycholesterol | |
| Inflammatory markers Brain        | Increased IL-1β               | |
| Effects of specific multi-nutrient diets: Compared to littermates on control (CO) diet |
|------------------------------------|--------------------------------|-----------------|
| Open field Behavior & activity    | Increased activity            | n.s.            |
| Morris water maze Learning & memory | Decreased anxiety             | |
| reverse MWM Learning & memory     | n.s.                          | n.s.            |
| Hippocampal 1H MRS Metabolite levels | n.s.                          | Decreased tCho/tCre |
| Immature neurons Hippocampus      | n.s.                          | Increased      |
| *effect in AβPP-PS1 only*         |                               | neurogenesis*   |
| Sterol analyses Serum             | Decreased cholesterol*        | Decreased cholesterol* |
| *effect in wild-type only*        | Decreased 24S-hydroxycholesterol | Decreased 24S-hydroxycholesterol |
| Brain                             | Decreased lahydroxycholesterol | Decreased lhydroxycholesterol |
| Fatty acid analysis Brain         | Increased n3 content          | Increased n3 content |
| Inflammatory markers Brain        | Increased OA content          | Increased OA content # |

1H MRS = proton magnetic resonance spectroscopy; tNAA = N-acetylaspartate and N-acetylaspartylglutamate; tCre = creatine and phosphocreatine; IL-1β = interleukin-1β; DEU diet = DHA, EPA, UMP diet; FC diet = Fortasyn® Connect diet; tCho = choline-containing compounds; n3 = omega-3 fatty acids; n6 = omega-6 fatty acids; OA = oleic acid (18:1n9); n.s. = not significant; # = tendency (0.5 < p < 0.7).

doi:10.1371/journal.pone.0075393.t003
contains therefore an extra episodic component [60,103]. Since episodic memory impairment is a major characteristic in early AD [104–106], our results in AβPP–PS1 mice resemble the problems that are present in early AD patients. Noteworthy are the relatively low escape latencies of both AβPP–PS1 and wild-type mice during the initial trials of the mWM acquisition training. Although wild-type mice displayed good short-term spatial memory for the NE platform location during the probe trial of the mWM, it appears that this information might not have been sufficiently consolidated in the long-term memory since they displayed more “random” search behavior during the initial mWM trials (resulting in lower escape latencies) than expected if animals had good long-term memory for the former platform location. One possible explanation could be that the mWM task as used in the current study was slightly too difficult to optimally master within 4 days of training. For mice, a mWM pool with a diameter of 120 cm and a platform of 10–12 cm in diameter (or even larger) is commonly used, resulting in a search area to target size of 144:1 to 100:1 (or even lower). In the current study, we used a pool with a diameter of 104 cm and a platform of 8 cm in diameter, resulting in a search area to target size of 169:1, thereby increasing the mWM task difficulty [107,108].

Previous studies have shown that n3 lc-PUFA intake may improve cognition in both mice and rats [58,109,110]. Besides n3 lc-PUFAs, other nutrients can also affect spatial memory performance. Supplementing CDP-choline or UMP and choline to rats improved spatial memory in the water maze [111,112]. In addition, transgenic mice fed vitamin E [113] or vitamin B3 [114] showed normalized escape latency in the water maze. Furthermore, a combination of vitamin E and folic acid prevented human Aβ1–42-induced impairment of water maze learning in 3-month-old male Scess mice [115]. However, in agreement with our current results, there are also some reports showing no effect of n3 lc-PUFA intake on learning and memory performance [89,116,117]. Moreover, most intervention studies based on single nutrient supplementation with n3 lc-PUFAs, B-vitamins or vitamin E have failed to show any protective effect on AD [39–41,118] or cognitive decline [119–121], except in some patients with mild AD [122,123]. Interestingly, clinical studies with the multi-nutrient FC supplementation have shown beneficial effects on memory performance in patients with mild AD [51–53], although we could not replicate these findings in our AβPP–PS1 mouse model when using the standard conventional measures of performance in the mWM. However, the FC diet did recently improve the search strategy of AβPP–PS1 mice in the acquisition of the mWM, by switching from predominantly random search strategies towards a more efficient search strategy, suggesting some beneficial effects of the FC diet on the ability to cope with cognitive impairment in the AβPP–PS1 mouse model [124].

1H MR spectroscopy revealed decreased tNAA/tCre levels in the hippocampus of 12-month-old AβPP–PS1 mice as compared to wild-type mice, in accordance with our previous results [76]. The reduction of tNAA levels is one of the most consistent findings using 1H MRS in AD patients [125–128] and in several transgenic AβPP animals models for AD [129–133], and is commonly interpreted as a result of neuronal dysfunction or neuronal loss [134,135]. Furthermore, many previous 1H MRS studies have found elevated levels of myo-Inositol (mI) in the temporal, parietal and occipital lobes of AD patients [126,128], which has been associated with enhanced inflammatory processes. Reports on mI levels in transgenic animals models are highly inconsistent, since disturbances in mI levels were found to occur at different ages in different transgenic species apparently depending on the interplay of mouse strain, transgene and disease progression [136]. For example, the AβPPswc (Tg2576) model and the AβPP–PS2N1411 (PS2A2P) model do not show any change in mI levels throughout life compared to age-matched wild-type mice, even though these animal models display decreased NAA levels in the frontal cortex at 19–24 months of age, when Aβ deposits are widespread [129,137]. In the case of the AβPPswc–PS1M146L model, one study reported the most profound increase in mI levels after 20 months of age [130], whereas another study reported a decrease in mI levels at 2.5 months of age as compared to age-matched wild-type mice [131]. In the current study and in our previous study [76], we did not observe any differences in the levels of mI+Glc between AβPP–PS1 and wild-type mice. In contrast, Chen and colleagues observed significantly increased levels of mI in 3-, 5- and 8-month-old AβPP–PS1swc1E9 mice, when pathology showed activation and proliferation of astrocytes in the frontal cortex and hippocampus [138,139]. The discrepancy between the results found by Chen et al. and our own findings are most likely due to differences in methodology, e.g. the field strength of the MR system, the acquisition parameters used, the exact position of the spectroscopic volume of interest, the age of the animals, and the amount of animals used.

Disturbances of several other metabolites have been found in AD patients as well, although the reports are inconsistent. Some studies identified elevated choline-containing compounds (tCho) and creatine (tCre) in AD patients [140–142], whereas others did not [125,143]. One possible explanation for the elevation of tCho in AD is increased membrane turnover due to neurodegenerative processes [144,145]. It has also been postulated that the elevation of the tCho peak is the consequence of membrane phosphatidylcholine catabolism in order to provide free choline for the chronically deficient acetylcholine production in AD [146,147]. In agreement with our current findings, no differences were observed between AβPP–PS1 and wild-type mice at any age tested in the levels of tCho [76,133,138]. Dietary intake with the FC diet significantly decreased the levels of tCho in AβPP–PS1 and wild-type mice, suggesting diminished membrane turnover. Since the FC diet provides precursors and cofactors in membrane synthesis and maintenance that are not supplemented in the CO and DEU diets, such as choline chloride and soy lecithin, these additional nutrients might underlie the decreased levels of tCho. 1H MRS studies to investigate the effect of the multi-nutrient FC diet on brain metabolites in mild AD patients are currently ongoing.

Dietary intervention with the FC diet, but not with the DEU diet, restored neurogenesis in AβPP–PS1 mice. Reduced hippocampal neurogenesis has been found previously in AβPP–PS1 mice beyond 8 months of age [99,100,148] and in AD patients [102,149,150]. In line with our results, previous studies have shown that n3 lc-PUFAs [151,152], folic acid [153,154], and vitamins and antioxidants [155,156] may promote neurogenesis. Since the FC diet did not affect neurogenesis in wild-type mice, our results could imply that this dietary intervention may especially be beneficial when neurogenesis is severely compromised. Dietary intervention with the FC diet might therefore be of interest for several other neurodegenerative and neurological disorders in which neurogenesis is impaired, such as Parkinson’s disease and major depression.

Quantitative real-time PCR revealed increased IL-1β mRNA levels in 12-month-old AβPP–PS1 mice as compared to age-matched wild-type mice. In response to brain injury or infection, IL-1β is both expressed by and targeted to many different cell types within the brain, such as microglia, astrocytes, endothelial cells, infiltrating leukocytes, neurons and oligodendrocytes [157–159]. IL-1β has been implicated to be at or near the top of the cytokine signaling cascade that initiates the neuroinflammatory
changes seen in AD (reviewed in [160,161]). It has been suggested that the initial burst of IL-1β production might actually have a beneficial role in AD, by enhancing the microglial clearance of amyloid plaques [161–163]. However, chronic elevation of IL-1β is detrimental, since IL-1β is capable of propagating inflammatory responses by increasing its own expression [161,162,164] and inducing the expression of several pro-inflammatory cytokines, such as TNF-α and IL-6 [163], and chemokines, such as MCP-1 [166,167]. Our results of increased IL-1β mRNA levels in 12-month-old AβPP-PS1 mice, but no changes (yet) in the mRNA levels of MCP-1, IL-6, TNF-α and CD36, might reflect the initial burst of IL-1β production in response to brain injury or toxic agents such as Aβ.

Surprisingly, IL-1β mRNA levels were also elevated in both AβPP-PS1 and wild-type mice in response to dietary intervention with the DEU and FC diets. This seems contradictory to the anti-inflammatory and immunosuppressive properties ascribed to n3 long-chain PUFA s, B vitamins and antioxidants [28,34,168]. However, IL-1β signaling has also been associated with neuroprotective mechanisms, including mediating the production of survival signals such as nerve growth factor [169,170] and mediating re-myelination of the central nervous system by stimulating oligodendrocytes proliferation [159,171]. Interestingly, results from our own lab indicate that both the DEU and FC diets prevent axonal disconnection and myelin degradation, determined by diffusion tensor MR imaging, in the 12-month-old AβPP-PS1 and wild-type mice used in the current study (Zerbi et al., submitted data). However, since prolonged elevation of IL-1β can initiate chronic neuroinflammatory processes, the question remains whether the effects of these multi-nutrient diets on IL-1β production are ultimately beneficial or detrimental in the AβPP-PS1 mouse model.

In conclusion, we showed that specific multi-nutrient diets can ameliorate some AD-related pathologies in 11–12-month-old AβPPsw/PSE1De9 mice. Although both diets were equally effective in changing brain fatty acid profiles and cholesterol metabolism, the diets differentially affected open field behavior, hippocampal metabolite levels and neurogenesis, suggesting that the effectiveness of specific nutrients may depend on the dietary context in which they are provided. The multi-nutrient enriched FC diet with DHA, EPA, UMP, phospholipids, choline, folic acid, vitamins B6, B12, C, E and selenium (Fortasyn® Connect; FC diet) was more effective than the DEU diet enriched with DHA, EPA and UMP in counteracting neurodegenerative aspects of AD and enhancing processes involved in neuronal maintenance and repair. Intervention with the FC diet might therefore be of interest for several other neurodegenerative and neurological disorders.

Acknowledgments
We would like to thank Janneke Mulders and Denise Tax for their excellent care giving of our mice. The authors would also like to acknowledge Carola Jansen (department of Anatomy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands) for her help with performing the PCR to genotype the AβPP-PS1 and wild-type mice. Furthermore, we would like to thank Andor Volten and Saak van Asten (department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands) for their technical support with the MR imaging. The authors would further like to acknowledge Zewen Zhang for her help with the qRT-PCR analyses (Department of General Internal Medicine, Radboud University Nijmegen Medical Centre, Nijmegen Institute for Infection, Inflammation and Immunity). We would also like to thank Nick van Wijk and Martin Balvers (Nutricia Advanced Medical Nutrition, Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands) for supplying the diets and for performing the brain fatty acid analysis, and Anja Kerkhofs (Institute for Clinical Chemistry and Clinical Pharmacology, University Clinics Bonn, Bonn, Germany) for performing the serum and brain steroid analysis.

Author Contributions
Conceived and designed the experiments: AJK DJ VZ. Performed the experiments: DJ VZ IACA MW AR XTF. Contributed reagents/materials/analysis tools: AJK AH PJD LMB DL LABJ. Wrote the paper: DJ AJK.

References
1. Wu L, Rosa-Neto P, Hsuong GY, Sadovnick AD, Masellis M, et al. (2012) Early-onset familial Alzheimer’s disease (EEOAD). Can J Neurol Sci 39: 436–445.
2. Tanzi RE, Bertram L. (2001) New frontiers in Alzheimer’s disease genetics. Neuron 32: 181–184.
3. Braak E, Griffin K, Ara K, Bohl E, Bratke H, et al. (1999) Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci 249 Suppl 3: 14–22.
4. Mattson MP (2004) Pathways towards and away from Alzheimer’s disease. Nature 430: 631–639.
5. de la Torre JC (2002) Vascular basis of Alzheimer’s pathogenesis. Ann N Y Acad Sci 977: 196–213.
6. Lidecka C. (2004) Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci 5: 347–360.
7. Skoog I, Gustafsson D (2006) Update on hypertension and Alzheimer’s disease. Neurol Res 28: 605–611.
8. Whitmer RA, Gustafson DR, Barrett-Conner E, Haan MN, Gunderson EP, et al. (2006) Central obesity and increased risk of dementia more than three decades later. Neurology 71: 1057–1064.
9. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D (2007) Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 85: 1142–1147.
10. Lee JH, O’Keefe JH, Lavic CJ, Marchiak R, Harris WS (2008) Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 83: 324–332.
11. Lavic CJ, Milani RV, Mehra MR, Ventura HO (2009) Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 54: 505–514.
12. Lauritzen L, Hansen HS, Jorgensen MH, Michaelen KF (2001) The essentiality of long n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res 40: 1–94.
13. Horrocks LA, Farooqui AA (2004) Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot Essent Fatty Acids 70: 361–372.
14. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, et al. (1997) Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42: 776–782.
15. Barbero-Gateau P, Leforeur N, Deschamps V, Pera K, Dartigues JF, et al. (2002) Fish, meat, and risk of dementia: a 12-yr cohort study. BMJ 325: 932–933.
16. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D (2007) Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 85: 1142–1147.
17. Lee JH, O’Keefe JH, Lavic CJ, Marchiak R, Harris WS (2008) Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 83: 324–332.
18. Lavic CJ, Milani RV, Mehta MR, Ventura HO (2009) Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 54: 505–514.
19. Lauritzen L, Hansen HS, Jorgensen MH, Michaelen KF (2001) The essentiality of long n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res 40: 1–94.
20. Horrocks LA, Farooqui AA (2004) Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot Essent Fatty Acids 70: 361–372.
21. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ (2002) Blood pressure response to fish oil supplementation: meta-regression analysis of randomized trials. J Hypertens 20: 1493–1499.
22. Harris WS (1997) n-3 fatty acids and serum lipoproteins: animal studies. Am J Clin Nutr 65: 1615S–1616S.
23. Sacks FM, Katan M (2002) Randomized clinical trials on the effects of dietary and supplemental n-3 fatty acids on plasma lipoproteins and cardiovascular disease. Am J Med 113 Suppl 9B: 128S–148S.
24. Leaf A, Kang JX, Xiao YF, Billman GE (2003) Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 107: 2646–2652.
25. Harris WS (1997) n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 65: 1658S–1658S.
26. Goodfellow J, Bellamy MF, Ramsey MW, Jones CJ, Lewis MJ (2000) Dietary supplementation with marine omega-3 fatty acids improve systemic large artery
endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 35: 265–270.

26. Okada N, Ushimaa H, Okayaanma A, Saitoh S, Nakagawa H, et al. (2005) Relation of long chain n-3 polysaturated fatty acid intake to serum high density lipoprotein cholesterol among Japanese men and Japanese-American men in Hawaii: the INTERLIPID study. Atherosclerosis 178: 371–379.

27. Calder PC (2000) Polysaturated fatty acids, inflammation, and immunity. J Nutr 130: 2589S–2624.

28. Farkas T, Kiajita K, Fodor E, Csegeri I, Lades E, et al. (2000) Docosahexaenoic acid-containing phospholipid molecular species in brains of vertebrates. Proc Natl Acad Sci U S A 97: 6362-6366.

29. Holguin S, Puskas LG, Zvara A, Haskel L., Jr., Barcelo-Coblijn G, et al. (2002) The role of n-3 polysaturated fatty acids in brain: modulation of rat brain gene expression by dietary n-3 fatty acids. Proc Natl Acad Sci U S A 99: 2691–2694.

30. Barcelo-Coblijn G, Hugyes E, Kiajita K, Puskas LG, Zvara A, et al. (2003) Modulation by docosahexaenoic acid of age-related changes in gene expression and molecular composition of rat brain phospholipids. Proc Natl Acad Sci U S A 100: 11132–11136.

31. Bouffe JM, Francois M, Youssouf D, Dumont O, Picotint M, et al. (1999) The effects of dietary alpha-linolenic acid on the composition of nerve-membranes, enzymatic activity, amplitude of electrophysiological parameters, resistance to poisons and performance of learning tasks in rats. J Nutr 119: 1880–1882.

32. Fontani G, Corradesschi F, Feruci A, Aiatti F, Migliorino S, et al. (2005) Cognitive and physiological effects of Omega-3 polysaturated fatty acid supplementation in healthy subjects. Eur J Clin Invest 35: 691–699.

33. Joseph JA, Shukitt-Hale B, Denisova NA, Prior RL, Cao G, et al. (1998) Long-term dietary supplementation with docosahexaenoic acid and other dietary constituents. Metabolism 57 Suppl 2: S6–10.

34. Bourre JM, Francois M, Youssouf D, Dumont O, Picotint M, et al. (2003) The function of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in Alzheimer's disease. J Neurosci 23: 257-267.

35. Fuji A, Matsumoto H, Yamamoto H (1996) Effect of vitamin B complex on neurotransmission and neurite outgrowth. Gen Pharmacol 27: 995–1000.

36. Rouille Y, Vincent B, Gobron S, Cucuat N, John GW (2005) Evidence for gamma-linolenic acid increase hippocampal concentrations of IL-4 and IL-10 in 12-month-old APP/PS1 transgenic mice. Neurobiol Dis 23: 113–190.

37. Scheltens P, Titulaer Muller MJ, Kerssens JJ, Weverling RJ, Hoogland J, et al. (1994) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APP/PS1/E9 mice. Neurobiol Dis 33: 482–498.

38. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11: 47–60.

39. Scudder J, Sanchez-Santed F, Fongthampruk RP, Donker A, Postmes P (1994) A behavioural analysis of rats with damage to the medial prefrontal cortex using the Morris water maze: evidence for behavioural flexibility, but not for impaired spatial navigation. Brain Res 652: 323–333.

40. Cavassali S, Deval S, Huguen C, van Ormondit D, Gravenor-Demilly D (2001) Kramer-Rao bounds: an evaluation tool for quantitation. NMR Biomed 14: 250–263.

41. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, et al. (2001) Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbcKm1. Behav Brain Res 127: 219–234.

42. Jansen D, Zerbi V, Janssen CI, Dederen PJ, Mutsaers MP, et al. (2013) A epsom salt: an index of anxiety in the mouse brain. J Neurosci 33: 720–724.

43. Tatemoto K, Yuhara H, Nakajima T, Okuma K, Matsuda M, et al. (1994) Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Nutr Health Aging 15: 720–724.

44. Scheltens P, Twisk JW, Bleus R, Scarpini E, von Arnim CA, et al. (2012) Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. Alzheimers Dement 8: 11–16.

45. Jankowsky JL, Shalt HH, Ratovitski T, Jenkins NA, Copeland NG, et al. (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biochem Eng 17: 157–165.

46. Wurtman RJ, Fadile DC, Hugues E, Kiajita K, Puskas LG, Zvara A, et al. (2003) Pankus MG, Wurtman RJ (2002) Dietary uridine enhances hippocampal gene expression of uracil nucleoside-phosphorylase in the brain of young adult rats. J Neurochem 80: 731–739.

47. Streijger F, Oerlemans F, Ellenbroek BA, Jost CR, Wieringa B, et al. (2005) Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbcKm1. Behav Brain Res 127: 219–234.

48. Wurtman RJ, Van der Zee CE, Centrella M, Reyjenier YD, et al. (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition, and cerebral vasculature in APP/PS1/E9 mice. Neurobiol Dis 33: 482–498.

49. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11: 47–60.

50. Scudder J, Sanchez-Santed F, Fongthampruk RP, Donker A, Postmes P (1994) A behavioural analysis of rats with damage to the medial prefrontal cortex using the Morris water maze: evidence for behavioural flexibility, but not for impaired spatial navigation. Brain Res 652: 323–333.

51. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, et al. (2001) Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbcKm1. Behav Brain Res 127: 219–234.

52. Jankowsky JL, Shalt HH, Ratovitski T, Jenkins NA, Copeland NG, et al. (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biochem Eng 17: 157–165.

53. Scheltens P, Titulaer Muller MJ, Kerssens JJ, Weverling RJ, Hoogland J, et al. (1994) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APP/PS1/E9 mice. Neurobiol Dis 33: 482–498.

54. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11: 47–60.

55. Scudder J, Sanchez-Santed F, Fongthampruk RP, Donker A, Postmes P (1994) A behavioural analysis of rats with damage to the medial prefrontal cortex using the Morris water maze: evidence for behavioural flexibility, but not for impaired spatial navigation. Brain Res 652: 323–333.

56. Scheltens P, Titulaer Muller MJ, Kerssens JJ, Weverling RJ, Hoogland J, et al. (1994) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APP/PS1/E9 mice. Neurobiol Dis 33: 482–498.

57. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11: 47–60.

58. Scudder J, Sanchez-Santed F, Fongthampruk RP, Donker A, Postmes P (1994) A behavioural analysis of rats with damage to the medial prefrontal cortex using the Morris water maze: evidence for behavioural flexibility, but not for impaired spatial navigation. Brain Res 652: 323–333.

59. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, et al. (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biochem Eng 17: 157–165.

60. Scheltens P, Titulaer Muller MJ, Kerssens JJ, Weverling RJ, Hoogland J, et al. (1994) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APP/PS1/E9 mice. Neurobiol Dis 33: 482–498.
111. De Bruin NM, Kiliaan AJ, De Wilde MC, Broersen LM (2003) Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats. Neurobiol Learn Mem 80: 63–79.

112. Teather LA, Wurtman RJ (2003) Dietary cytidine (5')-diphosphocholine supplementation protects against neurodegeneration and development of memory deficits in aging rats. Prog Neuropsychopharmacol Biol Psychiatry 27: 711–717.

113. Conte V, Uryu K, Fujimoto S, Yao Y, Rakach J, et al. (2004) Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following 12 months of dietary supplementation. J Neurochem 90: 730–764.

114. Green KN, Stefan JS, Martinez-Coria H, Sun X, Schreiber SS, et al. (2008) Niotimnamide restores cognition in Alzheimer’s disease transgenic mice via a mechanism involving sirin inhibition and selective reduction of Th23p1 inflammatory cytokines. J Neurosci 31: 1501–1510.

115. Figueiredo CP, Bica MA, Latini A, Prediger RD, Meineiro R, et al. (2011) Folic acid plus alpha-tocophorol mitigates amyloid-beta-induced neurotoxicity through modulation of mitochondrial complex activities. J Alzheimers Dis 24: 785–797.

116. Oksmann M, Ivonen V, Hogeys E, Amul T, Penke B, et al. (2006) Impact of different saturated fatty acid, polysaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 23: 503–572.

117. Arendash GW, Jensen MT, Salem Jr, H., Hussein N, Cracchiolo J, et al. (2007) A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer’s mice. Neurobiology 184: 298–302.

118. Farooqui A, Isaac MG, Clark AR, Rusted J, Tabet N (2012) Vitamin E for Alzheimer’s dementia and mild cognitive impairment. Cochrane Database Syst Rev 11: CD002854.

119. van der Rest O, Gelejme JMG, Kok EFJ, van Staveren WA, Dullemeijer C, et al. (2008) Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neur1: 430–438.

120. Rogers PJ, Appleton KM, Desser T, Peters TJ, Gunnell D, et al. (2008) No effect of n-3 long-chain polysaturated fatty acid (EPA and DHA) supplementation on depression-related and cognitive function: a randomized controlled trial. Br J Nutr: 421–431.

121. Dangour AD, Allen E, Elbourne D, Fasey N, Fletcher AE, et al. (2010) Effect of 2+ n-3 long-chain polysaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr: 1725–1732.

122. Kotani S, Sakaguchi E, Warabina S, Matsukawa N, Ishikura Y, et al. (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurol Sci: 136–149.

123. Freund-Levi Y, Basun H, Cederholm T, Faxen-Irving G, Garlind A, et al. (2006) Relationship of hippocampal N-acetyl aspartate level in aged APP(Swe)/PS1(dE9) transgenic mice with neurodegeneration. Brain Res 1449: 83–93.

124. Lovasic L, Bauschke H, Janus C (2005) Working memory impairment in a mouse model of Alzheimer’s disease. Brain Res 1019: 330–340.

125. Schuff N, Amendt L, Ezekiel F, Steinman SK, Tanabe J, et al. (1997) Changes in hippocampal N-acetyl aspartate and volume in Alzheimer’s disease. A protein MR-spectroscopic imaging and MRI study. Neurology 49: 1513–1521.

126. Grady CL, de Holland CL, Chatterji N, Oksenberg J, D’Arieto T, Watts RL, et al. (2008) Brain metabolism differs in Alzheimer’s disease and Parkinson’s disease dementia. Alzheimers Dement: 421–427.

127. Kantarcı K (2007) [1H magnetic resonance spectroscopy in dementia]. J Neurol Neurosurg Psychiatry 78: 152–159.

128. Watanabe T, Shimoi A, Akiyoshi I (2012) Hippocampal metabolites and memory performances in patients with amnestic mild cognitive impairment and Alzheimer’s disease. Neurobiol Learn Mem 97: 209–293.

129. Dedegolu A, Chou JS, Cormier K, Kowall NW, Jenkins BG (2004) Magnetic resonance spectroscopic analysis of Alzheimer’s disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 1012: 60–65.

130. Marjankina M, Carran GL, Wengnack TM, Henry PG, Bliss RL, et al. (2005) Monitoring disease progression in transgenic mouse models of Alzheimer’s disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 102: 11906–11910.

131. Oehl J, Spencer C, Wang FH, Anderson S, Westman E, et al. (2008) Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiol Aging 29: 1433–1439.

132. Mlynarik V, Capecchi M, Sun-Reimer L, Janssen S, Cudilab C, et al. (2012) Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer’s disease. J Alzheimers Dis 31 Suppl 3: 807–99.

133. Xu W, Zhan Y, Huang W, Wang X, Zhang S, et al. (2010) Reduction of hippocampal N-acetyl aspartate level in aged APP/PS1(PS1(de9)) transgenic mice is associated with degeneration of CA3 pyramidal neurons. J Neurosci Res 88: 3155–3160.

134. Molfett JR, Ross B, Ahrn P, Madhavanan CN, Nambudiri AM (2007) N- Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neuropsychopharmacol Biol Psychiatry 31: 89–131.

135. Block W, Traher F, Flacke S, Jussen T, Polf C, et al. (2002) In-vivo proton MR-spectroscopy of the human brain: assessment of N-acetylaspartate (NAA) reduction as a marker for neurodegeneration. Amino Acids 23: 317–323.
136. Choi IV, Lee SP, Guifoye DN, Helpern JA (2003) In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models. Neurochem Res 28: 987–1001.

137. von Kiraul M, Kunnecke B, Metzger F, Steiner G, Richards JG, et al. (2003) Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 18: 32–39.

138. Chen SQ, Cai Q, Shen YY, Wang PJ, Teng GJ, et al. (2012) Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice. Behav Brain Res 235: 1–6.

139. Chen SQ, Wang PJ, Ten GJ, Zhan W, Li MH, et al. (2009) Role of myoinositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice. Dement Geriatr Cogn Dis 28: 530–566.

140. Pfleiderer A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO (1999) In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: effects of normal aging. Magn Reson Med 41: 276–284.

141. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, et al. (2004) IH MR spectroscopy in common dementias. Neurology 63: 1393–1398.

142. Huang W, Alexander GE, Chang L, Shetty HU, Krasnuk LS, et al. (2010) Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology 57: 626–632.

143. Rose SE, de Zubicaray GI, Wang D, Galloway GJ, Chalk JB, et al. (1999) A (1)H MRS study of probable Alzheimer’s disease and normal aging: implications for longitudinal monitoring of dementia progression. Mag Reson Imaging 17: 291–299.

144. Moyerhoff DJ, MacKay S, Constans JM, Norman D, Van Dyke C, et al. (1994) Azoal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol 36: 40–47.

145. Ginsberg L, Atack JR, Rapoport SI, Gershfeld NL (1993) “Autocannibalism” of choline-containing membrane phospholipids in the pathogenesis of Alzheimer's disease: A hypothesis. Neurochem Int 7: 369–372.

146. Demars M, Hu YS, Gadadhar A, Lazarov O (2010) Impaired neurogenesis is an early event in the etiology of familial Alzheimer’s disease in transgenic mice. J Neurosci Res 88: 2103–2117.

147. Boekhoorn K, Joels M, Lucassen PJ (2006) Increased proliferation reflects glial neurogenesis in vitro and in vivo. J Neurosci Res 88: 2091–2102.

148. Kawasaki E, Hashimoto M, Shido O (2006) Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 139: 991–997.

149. Zhang H, Huang G, Liu H, Chang H, Wilson JS (2012) Folic acid enhances Notch signaling, hippocampal neurogenesis, and cognitive function in a rat model of cerebral ischemia. Nutr Neurosci 15: 55–61.

150. Dau UN (2000) Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimer’s disease— but how and why? Prostaglandins Leukot Essent Fatty Acids 78: 11–19.

151. Cipullo R, Ciarioni S, Coccioni T, Ambrogni P, Ferri P, et al. (2002) Tocopherols enhance neurogenesis in dentate gyrus of adult rats. Int J Vitam Nutr Res 72: 170–176.

152. Bonnet E, Touyarat K, Allou S, Pallet V, Higeret P, et al. (2000) Retinoic acid restores adult hippocampal neurogenesis and reverses spatial memory deficit in vitamin A deprived rats. PLoS One 3: e3487.

153. Higgins GA, Olschowka JA (1991) Induction of interleukin-1 beta mRNA in adult rat brain. Brain Res Mol Brain Res 9: 143–148.

154. Eriksson C, Van Dam AM, Lucassen PJ, Bol GJ, Winblad B, et al. (1999) Immunochemical localization of interleukin-1beta, interleukin-1 receptor antagonist and interleukin-1beta converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic acid. Neuroscience 93: 915–930.

155. Vela JM, Molina-Holgado E, Arevalo-Martin A, Alamaz G, Guaza C (2002) Interleukin-1 regulates proliferation and differentiation of oligodendrocyte progenitor cells. Mol Cell Neurosci 20: 489–502.

156. Manka RE, Griffin WS (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26: 549–554.

157. Shafiel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, et al. (2007) Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117: 1595–1604.

158. Matousek SB, Ghosh S, Shafiel SS, Kyrkanides S, Olschowka JA, et al. (2012) Chronic IL-1beta-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer’s disease without inducing overt neurodegeneration. J Neuroimmun Pharmacol 7: 156–164.

159. Shafiel SS, Griffin WS, O’Banion MK (2008) The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 5: 7.

160. Depeino A, Ferrari C, Pott Godoy MC, Tarelli R, Pitosi FJ (2005) Differential effects of interleukin-1beta on neurotoxicity, cytokine induction and glial reaction in specific brain regions. J Neuroimmunol 168: 96–110.

161. Basu A, Kresh JK, Levinson SW (2004) Interleukin-1: a master regulator of neuroinflammation. J Neurosci Res 78: 151–156.

162. Proescholdt MG, Chakravarty S, Foster JA, Foti SB, Briley EM, et al. (2002) Intracerebroventricular but not intravenously interleukin-1beta induces widespread vascular-mediated leukocyte infiltration and immune signal mRNA expression followed by brain-wide glial activation. Neuroscience 112: 731–749.

163. Shafiel SS, Carlson TJ, Olschowka JA, Kyrkanides S, Matousek SB, et al. (2007) Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J Neurosci 27: 9301–9309.

164. Song C, Manku MS, Horrobin DF (2008) Long-chain polysaturated fatty acids modulate interleukin-1beta-induced changes in behavior, monoaminergic neurotransmitters, and brain inflammation in rats. J Nutr 138: 954–963.

165. Juric DM, Carman-Kezma M (2001) Interleukin-1 beta, but not IL-1 alpha, mediates nerve growth factor secretion from rat astrocytes via type I IL-1 receptor. Int J Dev Neurosci 19: 673–683.

166. Stroppi PJ, Rothwell NJ (1995) Interleukin-1 beta attenuates excitatory amino acid-induced neurodegeneration in vitro: involvement of nerve growth factor. J Neurosci 15: 3468–3474.

167. Mason JL, Suzuki K, Chaplin DD, Matsushima GK (2001) Interleukin-1beta promotes repair of the CNS. J Neurosci 21: 7046–7052.

168. Reeves PG, Nielsen PH, Fahey GC, Jr. (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123: 1939–1951.